Drugs / NRTX-1001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06422923 | Nov 2024 → Jun 2027 expected | temporal lobe epilepsy | Neurona Therapeutics | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05135091 | Jun 2022 → Feb 2029 expected | temporal lobe epilepsy | Neurona Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-06 | Hopstem Biotechnology Inc. | Results 2026【四月精选】领域最新进展 hopstem.com ↗
Neurona Therapeutics 在宣布被优时比收购后，于4月22日在AAN年会上公布了核心管线 rezanecel（NRTX-1001）治疗耐药性内侧颞叶癫痫（MTLE）的Ⅰ/Ⅱ期临床积极新数据。 |
| 2024-06-28 | Hopstem Biotechnology Inc. | Regulatory 2024【六月精选】领域最新进展 hopstem.com ↗
Neurona Therapeutics 宣布，美国FDA已正式认定其 主要候选细胞疗法 NRTX-1001为再生医学先进疗法（RMAT） ，旨在治疗耐药性内侧颞叶癫痫（MTLE）患者。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-06 | Hopstem Biotechnology Inc. | 2026【四月精选】领域最新进展 hopstem.com ↗ |
| 2024-06-28 | Hopstem Biotechnology Inc. | 2024【六月精选】领域最新进展 hopstem.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRTX-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05135091 ↗ |
| Modality | Cell therapy | “NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line.” NCT05135091 ↗ |
| Route | Other | “single CT or MRI-guided intracerebral administration” NCT05135091 ↗ |